title: [Effects of antioxidant on reduction of hindlimb muscle atrophy induced by cisplatin in rats].
abstract: OBJECTIVE
  The purpose of this study was to examine the effects of Cu/Zn SOD on reduction of hindlimb muscular atrophy induced by cisplatin in rats.
  
  
  METHODS
  Forty-two rats were assigned to three groups; control group, Cisplatin (CDDP) group and cisplatin with Cu/Zn SOD (CDDP-SOD) group. At day 35 hindlimb muscles were dissected. Food intake, activity, withdrawal threshold, muscle weight, and Type I, II fiber cross-sectional area (CSA) of dissected muscles were measured. Relative SOD activity and expression of MHC and phosphorylated Akt, ERK were measured after dissection.
  
  
  RESULTS
  Muscle weight and Type I, II fiber CSA of hindlimb muscles in the CDDP group were significantly less than the control group. Muscle weight and Type I, II fiber CSA of hindlimb muscles, food intake, activity, and withdrawal thresholds of the CDDP-SOD group were significantly greater than the CDDP group. There were no significant differences in relative SOD activities of hindlimb muscles between the CDDP-SOD and CDDP groups. MHC expression and phosphorylated Akt, ERK of hindlimb muscles in the CDDP-SOD group were significantly greater than the CDDP group.
  
  
  CONCLUSIONS
  Cu/Zn SOD attenuates hindlimb muscular atrophy induced by cisplatin through increased food intake and activity. Increment of phosphorylated Akt, ERK may relate to attenuation of hindlimb muscular atrophy.
authors.affiliation: Department of Nursing, Christian College of Nursing, Gwangju, Korea. neoreva@hanmail.net.
authors.forename: Jin il
authors.initials: Ji
authors.lastname: Kim
authors.affiliation: College of Nursing, Seoul National University, Seoul, Korea.; Oita University of Nursing and Health Sciences, Oita, Japan.
authors.forename: Myoung-Ae
authors.initials: MA
authors.lastname: Choe
mesh_terms: D000818:Animals; D001835:Body Weight / Q000187:drug effects; D002945:Cisplatin / Q000633:toxicity*; D004195:Disease Models, Animal; D048049:Extracellular Signal-Regulated MAP Kinases / Q000378:metabolism; D006614:Hindlimb; D008297:Male; D018482:Muscle, Skeletal / Q000187:drug effects* / Q000201:enzymology / Q000378:metabolism; D009133:Muscular Atrophy / Q000139:chemically induced* / Q000378:metabolism / Q000473:pathology; D010766:Phosphorylation; D051057:Proto-Oncogene Proteins c-akt / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D011994:Recombinant Proteins / Q000096:biosynthesis / Q000235:genetics / Q000494:pharmacology; D013482:Superoxide Dismutase / Q000235:genetics / Q000378:metabolism / Q000494:pharmacology; D013481:Superoxides / Q000378:metabolism
chemical_list: D011994:Recombinant Proteins; D013481:Superoxides; D013482:Superoxide Dismutase; D051057:Proto-Oncogene Proteins c-akt; D048049:Extracellular Signal-Regulated MAP Kinases; D002945:Cisplatin
keywords: Antioxidant; Cisplatin; Muscular atrophy; Rat; Superoxide dismutase